🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 22 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 03/02/2006 | 35,00 | 35,36 | 34,43 | 34,54 | -1,54% | 2,66% | 1.318.800 |
| 02/02/2006 | 35,99 | 36,54 | 34,75 | 35,08 | -2,69% | 4,97% | 982.100 |
| 01/02/2006 | 35,53 | 36,63 | 35,53 | 36,05 | +0,92% | 3,10% | 1.102.400 |
| 31/01/2006 | 34,78 | 35,78 | 34,23 | 35,72 | +2,58% | 4,46% | 813.500 |
| 30/01/2006 | 35,98 | 36,25 | 34,61 | 34,82 | -3,14% | 4,56% | 982.400 |
| 27/01/2006 | 34,34 | 35,97 | 34,18 | 35,95 | +5,09% | 5,21% | 1.545.500 |
| 26/01/2006 | 34,00 | 34,33 | 33,60 | 34,21 | +1,57% | 2,15% | 689.100 |
| 25/01/2006 | 33,60 | 34,15 | 33,26 | 33,68 | +0,42% | 2,65% | 962.200 |
| 24/01/2006 | 33,54 | 33,75 | 33,00 | 33,54 | +0,24% | 2,24% | 1.062.400 |
| 23/01/2006 | 34,54 | 34,56 | 32,81 | 33,46 | -2,85% | 5,07% | 1.693.600 |
| 20/01/2006 | 35,10 | 35,69 | 34,01 | 34,44 | -0,72% | 4,79% | 1.589.700 |
| 19/01/2006 | 34,80 | 35,20 | 34,00 | 34,69 | +0,96% | 3,45% | 1.129.000 |
| 18/01/2006 | 32,96 | 34,60 | 32,06 | 34,36 | +2,29% | 7,71% | 1.232.800 |
| 17/01/2006 | 33,60 | 34,20 | 33,31 | 33,59 | -0,77% | 2,65% | 730.700 |
| 13/01/2006 | 33,65 | 33,97 | 33,23 | 33,85 | +0,53% | 2,20% | 916.100 |
| 12/01/2006 | 33,76 | 34,25 | 33,00 | 33,67 | -0,74% | 3,70% | 1.421.100 |
| 11/01/2006 | 34,25 | 34,98 | 33,87 | 33,92 | -0,35% | 3,24% | 1.987.800 |
| 10/01/2006 | 33,09 | 34,08 | 32,82 | 34,04 | +2,84% | 3,81% | 2.006.400 |
| 09/01/2006 | 31,93 | 34,25 | 31,32 | 33,10 | +5,82% | 9,18% | 4.799.000 |
| 06/01/2006 | 30,29 | 31,41 | 29,91 | 31,28 | +6,11% | 4,95% | 2.001.200 |
| 05/01/2006 | 28,36 | 29,51 | 28,03 | 29,48 | +4,13% | 5,22% | 1.292.800 |
| 04/01/2006 | 27,80 | 28,77 | 27,80 | 28,31 | +1,47% | 3,49% | 994.200 |
| 03/01/2006 | 27,88 | 28,20 | 26,50 | 27,90 | +0,83% | 6,10% | 1.218.100 |
| 30/12/2005 | 27,42 | 27,85 | 26,61 | 27,67 | +0,69% | 4,52% | 963.500 |
| 29/12/2005 | 28,20 | 28,26 | 27,44 | 27,48 | -2,28% | 2,91% | 517.100 |
| 28/12/2005 | 28,15 | 28,38 | 27,55 | 28,12 | -0,28% | 2,95% | 767.200 |
| 27/12/2005 | 28,90 | 29,10 | 27,99 | 28,20 | -2,05% | 3,84% | 612.800 |
| 23/12/2005 | 29,03 | 29,24 | 28,63 | 28,79 | -0,45% | 2,10% | 566.900 |
| 22/12/2005 | 27,98 | 29,00 | 27,84 | 28,92 | +3,62% | 4,15% | 1.112.900 |
| 21/12/2005 | 27,38 | 28,00 | 27,03 | 27,91 | +1,94% | 3,54% | 1.342.400 |